+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vitiligo - Pipeline Insight, 2021

  • ID: 4036727
  • Clinical Trials
  • May 2021
  • Region: Global
  • 70 Pages
  • DelveInsight

FEATURED COMPANIES

  • Amgen
  • Arrien Pharmaceuticals
  • Boston Pharmaceuticals
  • Clinuvel Pharmaceuticals
  • Dermira
  • Pfizer
This “Vitiligo - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Vitiligo Understanding


Vitiligo: Overview


Vitiligo is a complex pigment disorder that involves the skin, the hair, and occasionally the mucous membranes. It is a long-term condition where pale white patches develop on the skin. Vitiligo can affect any area of skin, but it commonly happens on the face, neck and hands. Vitiligo is a multifactorial disorder characterized by the loss of functional melanocytes. The diagnosis of vitiligo is primarily made on clinical grounds and is based on history, clinical presentation, and family history (vitiligo, autoimmune disorders). The most extensively characterized clinical markers of active, progressive disease include: Koebner's phenomenon, trichrome lesions, inflammatory lesions and confetti-like depigmentation. The optimal treatment of vitiligo will depend on the subtype of the disease, percent of body surface area (BSA) involved, effect on quality of life, and the perception of the patient concerning the risk to benefit ratio. These treatments include phototherapy, topical and systemic immunosuppressants, and surgical techniques, stabilizing depigmented lesions and stimulating repigmentation.

"Vitiligo - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vitiligo pipeline landscape is provided which includes the disease overview and Vitiligo treatment guidelines. The assessment part of the report embraces, in depth Vitiligo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Vitiligo R&D. The therapies under development are focused on novel approaches to treat/improve Vitiligo.
  • In September 2020, TAGCyx biotechnologies entered into a research collaboration with CAGE Bio for development of TAGX-0003 for treatment of dermatological autoimmune skin diseases. TAGX-0003 is a DNA aptamer possessing potent IFN-?antagonistic activity developed by TAGCyx and has already shown effective data in humanized autoimmune skin disease animal model such as alopecia areata when intra-dermally injected.

Vitiligo Emerging Drugs Chapters


This segment of the Vitiligo report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vitiligo Emerging Drugs


Ruxolitinib: Incyte Corporation

Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The therapy is currently under Phase III clinical development for the treatment of vitiligo.

PF-06651600: Pfizer

PF-06651600 was developed as an irreversible inhibitor of JAK3 with selectivity over the other three JAK isoforms. A high level of selectivity toward JAK3 is achieved by the covalent interaction of PF-06651600 with a unique cysteine residue (Cys-909) in the catalytic domain of JAK3, which is replaced by a serine residue in the other JAK isoforms. The molecule is currently in Phase II clinical evaluation for the treatment of vitiligo.

Vitiligo: Therapeutic Assessment


This segment of the report provides insights about the different Vitiligo drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Vitiligo


There are approx. 22+ key companies which are developing the therapies for Vitiligo. The companies which have their Vitiligo drug candidates in the most advanced stage, i.e. Phase II include, Incyte Corporation.

Phases


This report covers around 22+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vitiligo: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vitiligo therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vitiligo drugs.

Vitiligo Report Insights

  • Vitiligo Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Vitiligo Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Vitiligo drugs?
  • How many Vitiligo drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vitiligo?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vitiligo therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Vitiligo and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Incyte Corporation
  • Amgen
  • Boston Pharmaceuticals
  • Arcutis Biotherapeutics
  • Pfizer
  • Dermavant Sciences
  • Clinuvel Pharmaceuticals
  • Celgene
  • TWi Biotechnology
  • AXIM Biotechnologies
  • Arrien Pharmaceuticals
  • Dermira

Key Products

  • Ruxolitinib
  • AMG-714
  • BOS 475
  • ARQ-252
  • PF-06651600
  • Cerdulatinib
  • Afamelanotide
  • Apremilast
  • AC-1101
  • AX 1602
  • ARN-4079
  • QLT-450
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Arrien Pharmaceuticals
  • Boston Pharmaceuticals
  • Clinuvel Pharmaceuticals
  • Dermira
  • Pfizer

IntroductionExecutive Summary
Vitiligo: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Vitiligo - Analytical Perspective
In-depth Commercial Assessment
  • Vitiligo companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Vitiligo Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)
  • Comparative Analysis

Ruxolitinib: Incyte Corporation
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

PF-06651600: Pfizer
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

AC-1101: TWi Biotechnology
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical/Discovery Stage Products
  • Comparative Analysis

QLT-450: Dermira
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Vitiligo Key CompaniesVitiligo Key ProductsVitiligo- Unmet NeedsVitiligo- Market Drivers and BarriersVitiligo- Future Perspectives and ConclusionVitiligo Analyst ViewsVitiligo Key CompaniesAppendix
List of Tables
Table 1 Total Products for Vitiligo
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Vitiligo
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Incyte Corporation
  • Amgen
  • Boston Pharmaceuticals
  • Arcutis Biotherapeutics
  • Pfizer
  • Dermavant Sciences
  • Clinuvel Pharmaceuticals
  • Celgene
  • TWi Biotechnology
  • AXIM Biotechnologies
  • Arrien Pharmaceuticals
  • Dermira
Note: Product cover images may vary from those shown